Role of endothelins in congestive heart failure

Canadian Journal of Physiology and Pharmacology

Volumn 81, Issue 6, 2003, Pages 588-597

  Moe, Gordon W ^a   Rouleau, Jean L ^b   Nguyen, Quang T ^b   Cernacek, Peter ^c   Stewart, Duncan J ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Endothelin antagonists; Endothelins; Heart failure

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 5,6,8,13 TETRAHYDRO 1,6,9,14 TETRAHYDROXY 3 (2 HYDROXYPROPYL) 7 METHOXY 8,13 DIOXOBENZO[A]NAPHTHACENE 2 CARBOXYLIC ACID; AMBRISENTAN; BMS 193884; BOSENTAN; CI 1034; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENRASENTAN; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N [6 [2 (5 BROMO 2 PYRIMIDINYLOXY)ETHOXY] 5 (4 METHYLPHENYL) 4 PYRIMIDINYL] 4 (2 HYDROXY 1,1 DIMETHYLETHYL)BENZENESULFONAMIDE; NEUROHORMONE; SARAFOTOXIN; SITAXSENTAN; TBC 11252; TEZOSENTAN; UNCLASSIFIED DRUG;

ALDOSTERONE BLOOD LEVEL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DOG; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; GEL PERMEATION CHROMATOGRAPHY; HUMAN; IMMUNOREACTIVITY; LIVER TOXICITY; LOW DRUG DOSE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT;

ANIMALS; CLINICAL TRIALS; ENDOTHELINS; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, ENDOTHELIN;

EID: 0037899134     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y03-011     Document Type: Review

References (100)

1. Abassi, Z.A., Golomb, E., Bridenbaugh, R., and Keiser, H.R. 1993. Metabolism of endothelin-1 and big endothelin-1 by recombinant neutral endopeptidase EC.3.4.24.11. Br. J. Pharmacol. 109: 1024-1028.
2. American Heart Association. 2001. Heart and stroke statistical update: congestive heart failure.
3. Arai, H., Hori, S., Aramori, I., Ohkubo, H., and Nakanishi, S. 1990. Cloning and expression of a cDNA encoding an endothelin receptor. Nature (London), 348: 730-732.
4. Araki, M., Hasegawa, K., Iwai-Kanai, E., Fujita, M., Sawamura, T., Kakita, T., Wada, H., Morimoto, T., and Sasayama, S. 2000. Endothelin-1 as a protective factor against beta-adrenergic agonist-induced apoptosis in cardiac myocytes. J. Am. Coll. Cardiol. 36: 1411-1418.
5. A receptors for endothelin regulation. Biochem. Biophys. Res. Commun. 238: 861-865.
6. Belloni, A.S., Rossi, G.P., Andreis, P.G., Neri, G., Albertin, G., Pessina, A.C., and Nussdorfer, G.G. 1996. Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats. Hypertension, 27: 1153-1159.
7. Boulanger, C.M., Tanner, F.C., Bea, M.L., Hahn, A.W., Werner, A., and Luscher, T.F. 1992. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ. Res. 70: 1191-1197.
8. Cavero, P.G., Miller, W.L., Heublein, D.M., Margulies, K.B., and Burnett, J.C., Jr. 1990. Endothelin in experimental congestive heart failure in the anesthetized dog. Am. J. Physiol. 259: F312-F317.
9. CIBIS-II Investigators and Committee 1999. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet, 353: 9-13.
10. B receptor mediates both vasodilation and vasoconstriction in vivo. Biochem. Biophys. Res Commun. 186: 867-873.
11. Clozel, M., Ramuz, H., Clozel, J.P., Breu, V., Hess, P., Loffler, B.M., Coassolo, P., and Roux, S. 1999. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J. Pharmacol. Exp. Ther. 290: 840-846.
12. Cody, R.J., Haas, G.J., Binkley, P.F., Capers, Q., and Kelley, R. 1992. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation, 85: 504-509.
13. CONSENSUS Trial Study Group 1987. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N. Engl. J. Med. 316: 1429-1435.
14. Cowie, M.R., Mosterd, A., Wood, D.A., Deckers, J.W., Poole-Wilson, P.A., Sutton, G.C., and Grobbee, D.E. 1997. The epidemiology of heart failure. Eur. Heart J. 18: 208-225.
15. Dupuis, J. 2000. Endothelin receptor antagonists and their developing role in cardiovascular therapeutics. Can. J. Cardiol. 16: 903-910.
16. Dupuis, J., Stewart, D.J., Cernacek, P., and Gosselin, G. 1996. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation, 94: 1578-1584.
17. Dupuis, J., Moe, G.W., and Cernacek, P. 1998. Reduced pulmonary metabolism of endothelin-1 in canine tachycardia-induced heart failure. Cardiovasc. Res. 39: 609-616.
18. Fleminger, G., Bousso-Mittler, D., Bdolah, A., Kloog, Y., and Sokolovsky, M. 1989. Immunological and structural characterization of sarafotoxin/endothelin family of peptides. Biochem. Biophys. Res. Commun. 162: 1317-1323.
19. Fraccarollo, D., Hu, K., Galuppo, P., Gaudron, P., and Ertl, G. 1997. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation, 96: 3963-3973.
20. Galatius-Jensen, S., Wroblewski, H., Emmeluth, C., Bie, P., Haunso, S., and Kastrup, J. 1996. Plasma endothelin in congestive heart failure: a predictor of cardiac death? J. Card. Fail. 2: 71-76.
21. Givertz, M.M., Colucci, W.S., LeJemtel, T.H., Gottlieb, S.S., Hare, J.M., Slawsky, M.T., Leier, C.V., Loh, E., Nicklas, J.M., and Lewis, B.E. 2000. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation, 101: 2922-2927.
22. B receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation, 92: 357-363.
23. Huntington, K., Picard, P., Moe, G., Stewart, D.J., Albernaz, A., and Monge, J.C. 1998. Increased cardiac and pulmonary endothelin-1 mRNA expression in canine pacing-induced heart failure. J. Cardiovasc. Pharmacol. 31(Suppl. 1): S424-S426.
24. A receptor blockade on neurohormonal activation in congestive heart failure. Eur. Heart J. 22: 378. [Abstr.]
25. Ikegawa, R., Matsumura, Y., Tsukahara, Y., Takaoka, M., and Morimoto, S. 1990. Phosphoramidon, a metalloproteinase inhibitor, suppresses the secretion of endothelin-1 from cultured endothelial cells by inhibiting a big endothelin-1 converting enzyme. Biochem. Biophys. Res. Commun. 171: 669-675.
26. Inoue, A., Yanagisawa, M., Kimura, S., Kasuya, Y., Miyauchi, T., Goto, K., and Masaki, T. 1989a. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. U.S.A. 86: 2863-2867.
27. Inoue, A., Yanagisawa, M., Takuwa, Y., Mitsui, Y., Kobayashi, M., and Masaki, T. 1989b. The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression. J. Biol. Chem. 264: 14 954-14 959.
28. Iwanaga, Y., Kihara, Y., Hasegawa, K., Inagaki, K., Yoneda, T., Kaburagi, S., Araki, M., and Sasayama, S. 1998. Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats. Circulation, 98: 2065-2073.
29. Kaluski, E., Kobrin, I., Zimlichman, R., Marmor, A., Krakov, O., Milo, O., Frey, A., Kaplan, S., Krakover, R., Caspi, A., Vered, Z., and Cotter, G. 2003. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective multicenter, double-blind, placebo-controlled study J. Am. Coll. Cardiol 41: 204-210.
30. Kanse, S.M., Takahashi, K., Lam, H.C., Rees, A., Warren, J.B., Porta, M., Molinatti, P., Ghatei, M., and Bloom, S.R. 1991. Cytokine stimulated endothelin release from endothelial cells. Life Sci. 48: 1379-1384.
31. Kiowski, W., Sutsch, G., Hunziker, P., Muller, P., Kim, J., Oechslin, E., Schmitt, R., Jones, R., and Bertel, O. 1995. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet, 346: 732-736.
32. B receptors, and ECE and distribution of endothelin-1 in failing rat heart. Am. J. Physiol. 276: H1197-H1206.
33. B receptor-mediated clearance of endothelin-1? Life Sci. 62: 185-193.
34. Kohno, M., Murakawa, K., Yokokawa, K., Yasunari, K., Horio, T., Kurihara, N., and Takeda, T. 1989. Production of endothelin by cultured porcine endothelial cells: modulation by adrenaline. J. Hypertens. Suppl. 7: S130-S131.
35. Kourembanas, S., Marsden, P.A., McQuillan, L.P., and Faller, D.V. 1991. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J. Clin. Invest. 88: 1054-1057.
36. Kramer, B.K., Nishida, M., Kelly, R.A., and Smith, T.W. 1992. Endothelins. Myocardial actions of a new class of cytokines. Circulation, 85: 350-356.
37. Lerman, A., Kubo, S.H., Tschumperlin, L.K., and Burnett, J.C., Jr. 1992. Plasma endothelin concentrations in humans with endstage heart failure and after heart transplantation. J. Am. Coll. Cardiol. 20: 849-853.
38. Levin, E.R. 1995. Endothelins. N. Engl. J. Med. 333: 356-363.
39. Li, K., Stewart, D.J., and Rouleau, J.L. 1991. Myocardial contractile actions of endothelin-1 in rat and rabbit papillary muscles. Role of endocardial endothelium. Circ. Res. 69: 301-312.
40. Lin, H.Y., Kaji, E.H., Winkel, G.K., Ives, H.E., and Lodish, H.F. 1991. Cloning and functional expression of a vascular smooth muscle endothelin 1 receptor. Proc. Natl. Acad. Sci. U.S.A. 88: 3185-3189.
41. A receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation, 94: 2131-2137.
42. A receptor antagonist. Circulation, 101: 142-147.
43. Margulies, K.B., Hildebrand, F.L., Jr., Lerman, A., Perrella, M.A., and Burnett, J.C., Jr. 1990. Increased endothelin in experimental heart failure. Circulation, 82: 2226-2230.
44. Masaki, T., Miwa, S., Sawamura, T., Ninomiya, H., and Okamoto, Y. 1999. Subcellular mechanisms of endothelin action in vascular system. Eur. J. Pharmacol. 375: 133-138.
45. McMurray, J.J., Ray, S.G., Abdullah, I., Dargie, H.J., and Morton, J.J. 1992. Plasma endothelin in chronic heart failure. Circulation, 85: 1374-1379.
46. MERIT-HF Study Group 1999. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet, 353: 2001-2007.
47. Miyauchi, T., and Masaki, T. 1999. Pathophysiology of endothelin in the cardiovascular system. Annu. Rev. Physiol. 61: 391-415.
48. Moe, G.W., Albernaz, A., Naik, G.O., Kirchengast, M., and Stewart, D.J. 1998. Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure. Cardiovasc. Res. 39: 571-579.
49. Moe, G.W., and Armstrong, P. 1999. Pacing-induced heart failure: a model to study the mechanism of disease progression and novel therapy in heart failure. Cardiovasc. Res. 42: 591-599.
50. Mulder, P., Richard, V., Derumeaux, G., Hogie, M., Henry, J.P., Lallemand, F., Compagnon, P., Mace, B., Comoy, E., Letac, B., and Thuillez, C. 1997. Role of endogenous endothelin in chronic heart failure: effect of long- term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation, 96: 1976-1982.
51. A receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure. Cardiovasc. Res. 39: 600-608.
52. Mulder, P., Boujedaini, H., Richard, V., Derumeaux, G., Henry, J.P., Renet, S., Wessale, J., Opgenorth, T., and Thuillez, C. 2000. Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure. Circulation, 102: 491-493.
53. Nguyen, Q.T., Cernacek, P., Calderoni, A., Stewart, D.J., Picard, P., Sirois, P., White, M., and Rouleau, J.L. 1998. Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation, 98: 2323-2330.
54. O'Connell, J.B. 2000. The economic burden of heart failure. Clin. Cardiol. 23: III6-10.
55. O'Connor, C.M., Gattis, W.A., Adams, K.F.., Jr., Shah, M.R., Frey, A., and Gheorghiade, M. 2003. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the randomized intravenous study (RITZ-4). J. Am. Coll. Cardiol. In press.
56. B receptor antagonist in heart failure. Cardiovasc. Res 39: 617-624.
57. Pacher, R., Stanek, B., Hulsmann, M., Koller-Strametz, J., Berger, R., Schuller, M., Hartter, E., Ogris, E., Frey, B., Heinz, G., and Maurer, G. 1996. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J. Am. Coll. Cardiol. 27: 633-641.
58. Packer, M. 1992. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J. Am. Coll. Cardiol. 20: 248-254.
59. Packer, M., Carver, J.R., Rodeheffer, R.J., Ivanhoe, R.J., DiBianco, R., Zeldis, S.M., Hendrix, G.H., Bommer, W.J., Elkayam, U., Kukin, M.L., and. 1991. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med. 325: 1468-1475.
60. Packer, M., Caspi, A., and Charlon, V. 2001a. Multicenter, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure: results of the REACH-1 trial. Circulation, 98: I-3. [Abstr.]
61. Packer, M., Coats, A.J., Fowler, M.B., Katus, H.A., Krum, H., Mohacsi, P., Rouleau, J.L., Tendera, M., Castaigne, A., Roecker, E.B., Schultz, M.K., and DeMets, D.L. 2001b. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344: 1651-1658.
62. Pandey, A.S., Stewart, D.J., Cernacek, P., Dawood, F., Wen, W.H., and Liu, P. 1998. Chronic endothelin-1 blockade preserves myocardial contractility in dilated cardiomyopathy. J. Cardiovasc. Pharmacol. 31(Suppl 1): S306-S308.
63. Pfeffer, J.M., Finn, P.V., Zornoff, L.A., and Pfeffer, M.A. 2000. Endothelin-A receptor antagonism during acute myocardial infarction in rats. Cardiovasc. Drugs Ther. 14: 579-587.
64. Piacentini, L., Gray, M., Honbo, N.Y., Chentoufi, J., Bergman, M., and Karliner, J.S. 2000. Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein kinase C. J. Mol. Cell Cardiol. 32: 565-576.
65. Picard, P., Smith, P.J., Monge, J.C., Rouleau, J.L., Nguyen, Q.T., Calderone, A., and Stewart, D.J. 1998. Coordinated upregulation of the cardiac endothelin system in a rat model of heart failure. J. Cardiovasc. Pharmacol. 31(Suppl. 1): S294-S297.
66. Pousset, F., Isnard, R., Lechat, P., Kalotka, H., Carayon, A., Maistre, G., Escolano, S., Thomas, D., and Komajda, M. 1997. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur. Heart J. 18: 254-258.
67. Qi, X.L., Sia, Y.T., Stewart, D.J., Wei, G., Nguyen, Q.T., Cernacek, P., Picard, P., Sirois, M., and Rouleau, J.L. 2001. Myocardial contractile responsiveness to endothelin-1 in the post- infarction rat model of heart failure: effects of chronic quinapril. J. Mol. Cell. Cardiol. 33: 2023-2035.
68. Rich, M.W. 1997. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J. Am. Geriatr. Soc. 45: 968-974.
69. Rodeheffer, R.J., Lerman, A., Heublein, D.M., and Burnett, J.C., Jr. 1992. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin. Proc. 67: 719-724.
70. Saad, D., Mukherjee, R., Thomas, P.B., Iannini, J.P., Basler, C.G., Hebbar, L., Moreland, S., Webb, M.L., Powell, J.R., and Spinale, F.G. 1998. The effects of endothelin-A receptor blockade during the progression of pacing-induced congestive heart failure. J. Am. Coll. Cardiol. 32: 1779-1786.
71. Sakai, S., Yorikane, R., Miyauchi, T., Sakurai, T., Kasuya, Y., Yamaguchi, I., Sugishita, Y., and Goto, K. 1995. Altered production of endothelin-1 in the hypertrophied rat heart. J. Cardiovasc. Pharmacol. 26(Suppl. 3): S452-S455.
72. Sakai, S., Miyauchi, T., Kobayashi, M., Yamaguchi, I., Goto, K., and Sugishita, Y. 1996a. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature (London), 384: 353-355.
73. Sakai, S., Miyauchi, T., Sakurai, T., Kasuya, Y., Ihara, M., Yamaguchi, I., Goto, K., and Sugishita, Y. 1996b. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation, 93: 1214-1222.
74. Sakai, S., Miyauchi, T., Sakurai, T., Yamaguchi, I., Kobayashi, M., Goto, K., and Sugishita, Y. 1996c. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats. J. Am. Coll. Cardiol. 28: 1580-1588.
75. B receptors mediate contraction to endothelin-1 in human blood vessels. Circulation, 89: 1203-1208.
76. Shimada, K., Takahashi, M., and Tanzawa, K. 1994. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J. Biol. Chem. 269: 18 275-18 278.
77. Shubeita, H.E., McDonough, P.M., Harris, A.N., Knowlton, K.U., Glembotski, C.C., Brown, J.H., and Chien, K.R. 1990. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. J. Biol. Chem. 265: 20 555-20 562.
78. A receptor blockade in patients with congestive heart failure. ET 003 Investigators. J. Am. Coll. Cardiol. 35: 1745-1752.
79. Spinale, F.G., Walker, J.D., Mukherjee, R., Iannini, J.P., Keever, A.T., and Gallagher, K.P. 1997. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Beneficial effects on left ventricular and myocyte function. Circulation, 95: 1918-1929.
80. Stewart, D.J., Cernacek, P., Costello, K.B., and Rouleau, J.L. 1992. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation, 85: 510-517.
81. Suresh, D.P., Lamba, S., and Abraham, W.T. 2000. New developments in heart failure: role of endothelin and the use of endothelin receptor antagonists. J. Card. Fail. 6: 359-368.
82. Sutsch, G., Kiowski, W., Yan, X.W., Hunziker, P., Christen, S., Strobel, W., Kim, J.H., Rickenbacher, P., and Bertel, O. 1998. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation, 98: 2262-2268.
83. Sutsch, G., Bertel, O., Rickenbacher, P., Clozel, M., Yandle, T.G., Nicholls, M.G., and Kiowski, W. 2000. Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins. Am. J. Cardiol. 85: 973-976.
84. The Digitalis Investigator Group 1997. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N. Engl. J. Med. 336: 525-533.
85. The SOLVD Investigators 1991. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl. J. Med. 325: 293-302.
86. Tonnessen, T., Christensen, G., Oie, E., Holt, E., Kjekshus, H., Smiseth, O.A., Sejersted, O.M., and Attramadal, H. 1997. Increased cardiac expression of endothelin-1 mRNA in ischemic heart failure in rats. Cardiovasc. Res. 33: 601-610.
87. Tonnessen, T., Lunde, P.K., Giaid, A., Sejersted, O.M., and Christensen, G. 1998. Pulmonary and cardiac expression of preproendothelin-1 mRNA are increased in heart failure after myocardial infarction in rats. Localization of preproendothelin-1 mRNA and endothelin peptide. Cardiovasc. Res. 39: 633-643.
88. Torre-Amione, G., Young, J.B., Durand, J., Bozkurt, B., Mann, D.L., Kobrin, I., and Pratt, C.M. 2001. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation, 103: 973-980.
89. Tsutamoto, T., Wada, A., Maeda, Y., Adachi, T., and Kinoshita, M. 1994. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J. Am. Coll. Cardiol. 23: 1427-1433.
90. Underwood, R.D., Aarhus, L.L., Heublein, D.M., and Burnett, J.C., Jr. 1992. Endothelin in thoracic inferior vena caval constriction model of heart failure. Am. J. Physiol. 263: H951-H955.
91. Verhaar, M.C., Strachan, F.E., Newby, D.E., Cruden, N.L., Koomans, H.A., Rabelink, T.J., and Webb, D.J. 1998. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation, 97: 752-756.
92. B receptor antagonists in congestive heart failure. J. Am. Coll. Cardiol. 30: 1385-1392.
93. Wada, A., Tsutamoto, T., Ohnishi, M., Sawaki, M., Fukai, D., Maeda, Y., and Kinoshita, M. 1999. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism. Circulation, 99: 570-577.
94. Wei, C.M., Lerman, A., Rodeheffer, R.J., McGregor, C.G., Brandt, R.R., Wright, S., Heublein, D.M., Kao, P.C., Edwards, W.D., and Burnett, J.C., Jr. 1994. Endothelin in human congestive heart failure. Circulation, 89: 1580-1586.
95. Wei, C.M., Clavell, A.L., and Burnett, J.C. 1997. Atrial and pulmonary endothelin mRNA is increased in a canine model of chronic low cardiac output. Am. J. Physiol. 273: R838-R844.
96. Yamauchi-Kohno, R., Miyauchi, T., Hoshino, T., Kobayashi, T., Aihara, H., Sakai, S., Yabana, H., Goto, K., Sugishita, Y., and Murata, S. 1999. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function. Circulation, 99: 2171-2176.
97. Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., and Masaki, T. 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (London), 332: 411-415.
98. Yazaki, Y., and Yamazaki, T. 1997. Reversing congestive heart failure with endothelin receptor antagonists. Circulation, 95: 1752-1754.
99. Yoshida, K., Yasujima, M., Kohzuki, M., Kanazawa, M., Yoshinaga, K., and Abe, K. 1992. Endothelin-1 augments pressor response to angiotensin II infusion in rats. Hypertension, 20: 292-297.
100. Zolk, O., Quattek, J., Sitzler, G., Schrader, T., Nickenig, G., Schnabel, P., Shimada, K., Takahashi, M., and Bohm, M. 1999. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation, 99: 2118-2123.